Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 34739043.
- Also identified by DOI 10.1001/jama.2021.19885 and PMC identifier 8652594.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study assesses antispike (anti-S) IgG antibody titers before and after a third BNT162b2 dose (booster) in individuals aged 60 years and older in Israel.
Medical subject headings
- Antibodies, Viral
- COVID-19
- COVID-19 Vaccines
- Immunoglobulin G
- RNA, Messenger
- RNA, Viral
- SARS-CoV-2